<DOC>
	<DOC>NCT02211209</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 52 weeks in patients with Familial Chylomicronemia Syndrome</brief_summary>
	<brief_title>The APPROACH Study: A Study of Volanesorsen (Formerly ISIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type I</mesh_term>
	<criteria>History of chylomicronemia A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia) Fasting triglycerides ≥ 750 mg/dL (8.4 mmol/L) at Screening Diabetes mellitus if newly diagnosed or if HbA1c ≥ 9.0% Other types of severe hypertriglyceridemia Active pancreatitis within 4 weeks of screening Acute Coronary Syndrome within 6 months of screening Major surgery within 3 months of screening Treatment with Glybera therapy within 2 years of screening Previous treatment with ISISAPOCIIIRx Have any other conditions in the opinion of the investigator which could interfere with the patient participating in or completing the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>